NCT03093116招募中1 期
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 500
- 试验地点
- 302
- 主要终点
- Overall Response Rate (ORR) Phase 2
研究概览
简要总结
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction.
Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
详细描述
In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts:
- EXP-1: ROS1 TKI-naïve ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed
- EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to one prior line of a ROS1 TKI. Must have received one prior line of platinum based chemotherapy OR one prior line of platinum based chemotherapy in combination with immunotherapy before or after a ROS1 TKI
- EXP-3: 2 Prior ROS1 TKIs AND NO Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to 2 prior lines of a ROS1 TKI treatment. No prior lines of chemotherapy or immunotherapy are allowed.
- EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy. Disease progression or intolerant to one prior line of a ROS1 TKI. No prior lines of chemotherapy or immunotherapy are allowed.
- EXP-5: TRK TKI-naïve NTRK+ solid tumors. Any number of prior lines of chemo or immunotherapy is allowed.
- EXP-6: TRK TKI-pretreated NTRK+ solid tumors. Disease progression, or intolerant to 1 or 2 prior TRK TKIs. Any number of prior lines of chemo- or immunotherapy are allowed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 12 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Key Inclusion Criteria:
- •Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.
- •Age ≥18 (or age ≥ 20 of age as required by local regulation).
- •Capability to swallow capsules intact (without chewing, crushing, or opening).
- •At least 1 measurable target lesion according to RECIST version 1.
- •CNS-only measurable disease as defined by RECIST version 1.1 is allowed.
- •Prior cytotoxic chemotherapy is allowed.
- •Prior immunotherapy is allowed.
- •Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to
- •Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
- •Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
- •Life expectancy ≥ 3 months.
- •PHASE 2 Key Inclusion Criteria
- •Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.
- •Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:
- •a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.
- •Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.
- •a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.
- •Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-
- •Age ≥12 (or age ≥ 20 as required by local regulation).
- •Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to
- •At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.
- •Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and
排除标准
- •i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors
- •Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
- •Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
- •Life expectancy ≥ 3 months.
- •Key Exclusion Criteria PHASE 1 and PHASE 2
- •Concurrent participation in another therapeutic clinical trial.
- •Symptomatic brain metastases or leptomeningeal involvement.
- •History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.
- •Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry
- •Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2
- •Any of the following cardiac criteria:
- •Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.
- •Known active infections (bacterial, fungal, viral including HIV positivity).
- •Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
- •Peripheral neuropathy of CTCAE ≥grade
- •History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.
研究组 & 干预措施
Repotrectinib (TPX-0005)
Experimental
Phase 1
Oral repotrectinib (TPX-0005):
Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study.
Phase 2
Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts
- EXP-1: ROS1 TKI-naïve ROS1+ NSCLC
- EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC
- EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO)
- EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO)
- EXP-5: TRK TKI-naïve NTRK+ solid tumors
- EXP-6: TRK TKI-pretreated NTRK+ solid tumors
干预措施: Oral repotrectinib (TPX-0005) (Drug)
结局指标
主要结局
Overall Response Rate (ORR) Phase 2
时间窗: Two to three years after first dose of repotrectinib dose
To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)
Dose limiting toxicities (DLTs) (Phase 1)
时间窗: Within 28 days of the first repotrectinib dose
Define the dose limiting toxicities (DLTs) (Phase 1)
Recommended Phase 2 Dose (RP2D) (Phase 1)
时间窗: Within 28 days of the last patient dosed in escalation
To determine the RP2D (Phase 1)
次要结局
- Progression free survival (PFS) (Phase 2)(Approximately three years)
- Overall survival (OS) (Phase 2)(Approximately three years)
- Area under the plasma concentration time curve (AUC) of repotrectinib (TPX-0005) (Phase 1)(Up to 72 hours post dose)
- Maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)(Up to 24 hours post dose)
- Maximum plasma concentration (CMAX) of repotrectinib (TPX-0005) (Phase 1)(Up to 72 hours post dose)
- Duration of response (DOR) (Phase 2)(Approximately three years)
- Maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)(Up to 72 hours post dose)
- Intracranial objective response rate (Phase 2)(Approximately three years)
- Area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)(Up to 72 hours post dose)
- Area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)(Up to 24 hours post dose)
- Plasma concentration of repotrectinib following administration at RP2D (Phase 2)(Pre dose and 4 hours post dose)
- Preliminary objective response rate (ORR) (Phase 1)(Approximately three years)
- Clinical benefit rate (CBR) (Phase 2)(Approximately three years)
研究者
研究点 (302)
Loading locations...
相似试验
已完成
1 期
A Dose Escalation Study in Adult Patients With Advanced Solid MalignanciesAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or FusionAdvanced Solid Tumors With FGFR1 AmplicationAdvanced Solid Tumors With FGFR2 AmplicationAdvanced Solid Tumors With FGFR3 MutationNCT01004224Novartis Pharmaceuticals208
Unknown
1 期
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3804 in Subjects With Advanced Malignant TumorsAdvanced Malignant TumorsNCT04128085Chia Tai Tianqing Pharmaceutical Group Co., Ltd.30
Unknown
1 期
A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 InjectionAdvanced Solid TumorNCT04144855Chia Tai Tianqing Pharmaceutical Group Co., Ltd.40
已完成
1 期
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaNCT01410513Sanofi37
已完成
1 期
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder CancerSolid TumorsNCT02240238NanoCarrier Co., Ltd.119
相关资讯
Repotrectinib Recommended for EU Approval in ROS1+ NSCLC and NTRK+ Solid Tumors- The EMA's CHMP recommended repotrectinib for adult patients with advanced ROS1-positive NSCLC, addressing the unmet need for new therapies in this population.
- Repotrectinib is also recommended for NTRK fusion-positive solid tumors in adult and pediatric patients (12+), particularly after prior NTRK inhibitor treatment.
- The recommendation is based on TRIDENT-1 and CARE trials, demonstrating durable activity and robust responses in both ROS1-positive NSCLC and NTRK-positive solid tumors.
- Repotrectinib previously received FDA approval for ROS1-positive NSCLC (November 2023) and NTRK-positive solid tumors (accelerated approval, June 2024).last yearCHMP Recommends Repotrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors in Europe- The European Medicines Agency's CHMP has recommended repotrectinib (Augtyro) for ROS1-positive advanced non-small cell lung cancer (NSCLC) in adults.
- Repotrectinib is also recommended for NTRK gene fusion-positive advanced solid tumors in adults and children (12+) after prior NTRK inhibitor treatment or when other options are limited.
- The recommendation is based on TRIDENT-1 and CARE trial data, demonstrating clinically meaningful overall response rates in both ROS1+ NSCLC and NTRK+ solid tumors.
- The European Commission is expected to make a final decision in January 2025, potentially bringing a new treatment option to EU patients.last year